SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.17847452 USD and is down -3.32 over the last 24 hours. It is currently trading on 1894 active market(s) with $2,362,443,159.56 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp underperformance and choppy decline are driving discussion, with traders debating broader crypto weakness and midterm-related uncertainty over the Clarity Act and regulatory outlook. Bearish frustration over stagnant performance, Ripples token sales and perceived utility is countered by dip-buyers and long-term holders.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwires quarterly results are driving attention: revenue came in below expectations, while gross margins and backlog reached records and full-year guidance was reaffirmed. Bulls view the shortfall as a timing issue and point to improving operations; skeptics question whether the company can convert its backlog into revenue and reach profitability.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs strong quarterly results, raised full-year revenue outlook, and expanding backlog are driving a sharp rebound in the shares. Traders are encouraged by growth and commercial momentum, while others question revenue quality, cash burn, dilution, and whether the rally can last.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charters third-quarter results are drawing attention, particularly worsening broadband subscriber losses and a large franchise impairment that contributed to a reported loss. Bearish traders see continued customer erosion, debt and the Cox integration as risks, while bulls point to anticipated cost savings, mobile growth and cash flow as potential offsets.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axons sharp selloff follows a Q3 earnings miss and a lower full-year outlook, with federal Dedrone deployments delayed and expected to shift out of 2026. Traders are debating whether the drop is an overreaction to contract timing or a valuation reset, while also raising concerns about margins and stock-based compensation; some are buying the dip as others expect further downside.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A strong quarterly earnings beat and raised revenue outlook, powered by demand for Mounjaro and Zepbound, have driven attention to Lillys rally and record highs. Bulls point to continued GLP-1 growth and pipeline prospects, while skeptics flag the premium valuation, pricing pressure, and weaker-than-expected Foundayo uptake.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyxs quarterly results and restructuring are driving attention: the company reported a modest earnings and revenue miss, announced a roughly 20% workforce reduction and deeper R&D cuts, and reaffirmed its 2027 profitability goal. Traders are split between viewing the cost reductions and new therapy launches as progress and worrying about the miss, pipeline setbacks, and weak share-price reaction.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports priced stock and convertible-note offering is driving the discussion, with traders debating the dilution and why the company is raising capital despite its cash runway. Some bulls point to recent insider buying and positive Phase 2 results for RAP-219, while others worry the financing could weigh on shares.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Fireflys large engine, technology-licensing and engineering-support agreement with AST SpaceMobile for its planned heavy-lift rocket is driving attention. Traders largely view the partnership as validation of Fireflys propulsion business and a boost to its backlog, while some question the deals funding and share components and whether either company can execute its rocket plans.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

A rebound and breakout in Home Depot shares has traders focused on technical momentum and a possible rotation into housing-related stocks. Bulls see the move continuing, while skeptics point to high rates and a sluggish housing market as risks to its staying power.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present data from the VRDN-008 phase 1...

Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 39.7% in Viridian Therapeutics (VRDN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of +19.80% and +348.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the third quarter ended September 30...

Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates

Arvinas (ARVN) delivered earnings and revenue surprises of -2.50% and -98.07%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on...

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual...

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30...

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.read more...

$VRDN Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.81 down -138.24% YoY
• Reported revenue of $25.75M down -63.51% YoY

Stocktwits

Viridian Therapeutics Inc

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.81 down -138.24% YoY
• Reported revenue of $25.75M down -63.51% YoY

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$0.81 down -138.24% YoY
• Reported revenue of $25.75M down -63.51% YoY

Viridian Therapeutics reported Q3 2026 net loss of $101.2M versus $34.6M and SG&A expenses of $57.6M versus $24.3M; disclosures cite limited product-sales history and commercial capability risks.

Viridian Therapeutics reported Lumvoa revenue of $24.7M and more than 100 patients on therapy, permanent J-code assignment, and pipeline milestones for elegrobart and VRDN-292.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval  

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Lumvoa is the first treatment approved for patients with TED regardless of whether the disease is in its active (early) or chronic (long-term) stage.</li><li>Physicians can begin prescribing Lumvoa immediately, the company said.</li><li>TED is a rare autoimmune condition that causes painful inflammation and swelling around the eyes, leading to bulging, double vision, discomfort, and in some cases, vision problems.</li></ul><p>Shares of Viridian Therapeutics Inc (VRDN) jumped 6% after-hours on Friday after the U.S. Food and Drug Administration approved its drug Lumvoa for the treatment of thyroid eye disease.</p><p>The drug is now available by prescription and marks the company’s first approved medicine and first commercial product.</p><h2 class="st-heading-2">New Option For Active And Chronic Disease</h2><p>TED is a rare autoimmune condition that causes painful inflammation and swelling around the eyes, leading to bulging, double vision, discomfort, and in some cases, vision problems. Lumvoa is the first treatment approved for patients with TED regardless of whether the disease is in its active (early) or chronic (long-term) stage.</p><h2 class="st-heading-2">Strong Results In Key Trials</h2><p>The approval was based on two large late-stage studies — THRIVE in active TED and THRIVE-2 in chronic TED. In both trials, Lumvoa met all primary and secondary goals. Patients saw rapid reductions in eye bulging and double vision, with improvements beginning as early as three weeks. The drug is given as five intravenous infusions over 12 weeks.</p><h2 class="st-heading-2">Immediate Launch And Patient Support</h2><p>Physicians can begin prescribing Lumvoa immediately, the company said. Viridian has launched ViridianCares, a patient support program that offers insurance navigation, financial assistance, and dedicated support staff to help eligible patients access treatment.</p><h2 class="st-heading-2">Company And Expert Reaction</h2><p>“This approval represents a major step forward for people living with thyroid eye disease,” said Steve Mahoney, President and CEO of Viridian. “Lumvoa was designed with patients in mind and addresses a clear need across the full spectrum of the disease.”</p><p>In addition to Lumvoa, Viridian is advancing VRDN-003, a subcutaneous anti-IGF-1R antibody designed for self-administration via autoinjector. The company recently reported positive topline results from two pivotal late-stage trials in active and chronic thyroid eye disease.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around VRDN stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.</p><p>A Stocktwits user cheered the news as “massive” and recommended watching the stock next week.</p><p><stembedurl>https://www.stocktwits.com/Daniel_2025/message/657668888</stembedurl></p><p>According to data from Koyfin, 16 of the 17 analysts covering VRDN stock rate it ‘Buy’ or higher, while one rates it ‘Hold.’ The 12-month average price target on the stock is $33.94, representing a potential upside of about 90% from the last closing price.</p><p><a href="https://stocktwits.com/symbol/VRDN">VRDN stock</a> is down 42% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/upc-stock-surges-after-hours-whats-driving-the-rally/cZ12TA7R7WB">UPC Stock Surges 288% After Hours — What’s Driving The Rally?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Viridian Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The FDA approved Viridian’s Lumvoa for the treatment of thyroid eye disease. 

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$28.49
Prev Close	$28.55
Open	$28.66
Dividend Yield	0.00%
50-Day Moving Average	$21.97
Beta	1.15
Avg. Volume	2.1M
PE Ratio	-6.82

52-Week High	$34.29
52-Week Low	$13.18
Market Capitalization	$3.24B
EPS (Annual)	-$3.32
Price to Book	6.70
Revenue Per Employee	$281,146.83

Feed

News

Sentiment

Earnings

Fundamentals

Info

VRDN Fundamentals